Some investors asked Sannuo Biotech. The company has confirmed that overseas CGM has begun to contribute profits. In the context of the Abbott UPC ban, which regions will the contributions come from? Has the Abbott patent objection application submitted to the EPO currently received a notice of acceptance or entered the substantive examination stage? On November 12, the company replied that the company's CGM products have now completed compliance registration in 60 countries and regions around the world, and commercialized sales in more than 90 countries including Turkey, India, Thailand, and Saudi Arabia; in response to the patent lawsuit and temporary ban brought by Abbott in the European Unified Patent Court, the scope of the ban is limited to sales of corresponding CGM products within the UPC jurisdiction, and does not affect the normal development of the company's business in other countries and regions.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.